175 related articles for article (PubMed ID: 16464792)
1. Gastrin-releasing-peptide in neuroendorine tumours.
Granberg D; Skogseid B; Welin S; Orlefors H; Oberg K; Wilander E
Acta Oncol; 2006; 45(1):23-7. PubMed ID: 16464792
[TBL] [Abstract][Full Text] [Related]
2. Gastrin releasing peptide in human neuroendocrine tumours.
Bostwick DG; Bensch KG
J Pathol; 1985 Dec; 147(4):237-44. PubMed ID: 3003308
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects.
Wilander E; Lundqvist M; Oberg K
Prog Histochem Cytochem; 1989; 19(2):1-88. PubMed ID: 2662260
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours.
Jakobsen AM; Andersson P; Saglik G; Andersson E; Kölby L; Erickson JD; Forssell-Aronsson E; Wängberg B; Ahlman H; Nilsson O
J Pathol; 2001 Nov; 195(4):463-72. PubMed ID: 11745679
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract.
Fahrenkamp AG; Wibbeke C; Winde G; Ofner D; Böcker W; Fischer-Colbrie R; Schmid KW
Virchows Arch; 1995; 426(4):361-7. PubMed ID: 7599788
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis.
Wang DG; Johnston CF; Anderson N; Sloan JM; Buchanan KD
J Pathol; 1995 Apr; 175(4):397-401. PubMed ID: 7790993
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.
Oberg K; Astrup L; Eriksson B; Falkmer SE; Falkmer UG; Gustafsen J; Haglund C; Knigge U; Vatn MH; Välimäki M;
Acta Oncol; 2004; 43(7):626-36. PubMed ID: 15545183
[TBL] [Abstract][Full Text] [Related]
8. [Prevalence of the neuroendocrine phenotype in thymus neoplasms].
Ferolla P; Urbani M; Ascani S; Puma F; Ribacchi R; Battista Bolis G; Santeusanio F; Daddi G; Angeletti G; Avenia N
Chir Ital; 2002; 54(3):351-4. PubMed ID: 12192931
[TBL] [Abstract][Full Text] [Related]
9. Primary neuroendocrine carcinomas of the thymus.
Klemm KM; Moran CA
Semin Diagn Pathol; 1999 Feb; 16(1):32-41. PubMed ID: 10355652
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
11. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.
Perry KD; Reynolds C; Rosen DG; Edgerton ME; T Albarracin C; Gilcrease MZ; Sahin AA; Abraham SC; Wu Y
Histopathology; 2011 Oct; 59(4):619-30. PubMed ID: 22014043
[TBL] [Abstract][Full Text] [Related]
12. Tumour biology and histopathology of neuroendocrine tumours.
Klöppel G
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):15-31. PubMed ID: 17382263
[TBL] [Abstract][Full Text] [Related]
13. Renal neuroendocrine tumours: a clinicopathological study.
Lane BR; Chery F; Jour G; Sercia L; Magi-Galluzzi C; Novick AC; Zhou M
BJU Int; 2007 Nov; 100(5):1030-5. PubMed ID: 17784891
[TBL] [Abstract][Full Text] [Related]
14. Immunostaining of gastric cancer with neuroendocrine differentiation: Reg IV-positive neuroendocrine cells are associated with gastrin, serotonin, pancreatic polypeptide and somatostatin.
Sentani K; Oue N; Noguchi T; Sakamoto N; Matsusaki K; Yasui W
Pathol Int; 2010 Apr; 60(4):291-7. PubMed ID: 20403031
[TBL] [Abstract][Full Text] [Related]
15. Approach to the diagnosis of neuroendocrine lung neoplasms: variabilities and pitfalls.
Hammar SP
Semin Thorac Cardiovasc Surg; 2006; 18(3):183-90. PubMed ID: 17185177
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin expression in neuroendocrine tumours of the gastrointestinal tract with multiple endocrine neoplasia type 1.
Raffel A; Krausch M; Cupisti K; Gerharz CD; Eisenberger CF; Knoefel WT
Horm Metab Res; 2005 Oct; 37(10):653-5. PubMed ID: 16278790
[TBL] [Abstract][Full Text] [Related]
17. Imaging of neuroendocrine tumours (CT/MR/US).
Rockall AG; Reznek RH
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):43-68. PubMed ID: 17382265
[TBL] [Abstract][Full Text] [Related]
18. Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids.
Cunningham RT; Pogue KM; Curry WJ; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1999 Feb; 187(3):321-5. PubMed ID: 10398086
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the p16INK4a/cyclin D1/RB pathway in gastrointestinal tract endocrine tumors.
Li AF; Li AC; Tsay SH; Li WY; Liang WY; Chen JY
Am J Clin Pathol; 2008 Oct; 130(4):535-42. PubMed ID: 18794045
[TBL] [Abstract][Full Text] [Related]
20. Expression of connective tissue growth factor and IGF1 in normal and neoplastic gastrointestinal neuroendocrine cells and their clinico-pathological significance.
Kaltsas GA; Cunningham JL; Falkmer SE; Grimelius L; Tsolakis AV
Endocr Relat Cancer; 2011 Feb; 18(1):61-71. PubMed ID: 20959439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
